> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Janssen Scraps RSV Vaccine Development
- URL: https://www.fdaweb.com/janssen-scraps-rsv-vaccine-development/
- Published: 2023-03-29T12:00:00.000Z
- Updated: 2026-09-14T18:22:32.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5154093

Janssen Pharmaceutical says that due to business concerns it is scrapping development of an investigational respiratory syncytial virus adult vaccine and discontinuing the related Phase 3 [EVERGREEN study](https://c212.net/c/link/?t=0&l=en&o=3821295-1&h=2168309691&u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04908683&a=EVERGREEN+study&ref=fdaweb.com). The decision, it says, was made after the company reviewed its “portfolio to prioritize the most transformational assets for ongoing investment, and an assessment of the respiratory syncytial virus (RSV) vaccine landscape… The decision to discontinue the company’s RSV adult vaccine program is part of a broader effort to make strategic choices for its pipeline and research and development (R&D) investments to focus on medicines with the greatest potential benefit to patients.”